Pharmaceutical News

RSS

Experimental obesity drug a success for Danish company

An experimental obesity drug manufactured by a Danish company appears to be a success.

20 Nov 2007

Pfizer wins day in court over Celebrex

Drug giant Pfizer has won a court ruling in the United States which could limit the lawsuits the company might possibly face over claims that its painkiller Celebrex caused heart attacks and strokes.

20 Nov 2007

New non-addictive pain-killers

Two University of Adelaide pharmacologists working with one the world's leading neuroscientists have helped pave the way for the development of new pain-killing drugs that are not addictive.

20 Nov 2007

Spectral announces license agreement with Bio-Rad Pasteur S.A.

Spectral Diagnostics Inc. has announced that it has entered into a non-exclusive license and material supply agreement with Bio-Rad Pasteur S.A., a leader in the manufacturing and distribution of a broad range of products for the life science research and clinical diagnostics markets.

20 Nov 2007

Schering-Plough acquires Organon BioSciences

Schering-Plough Corporation has announced that it has completed the acquisition of Organon BioSciences N.V., creating a stronger combined company with broader human and animal health portfolios, an enhanced pipeline and increased R&D capabilities. Schering-Plough's agreement to acquire Organon BioSciences was announced on March 12, 2007.

20 Nov 2007

U.S. approval of Nexavar (sorafenib) for inoperable liver cancer

The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable.

19 Nov 2007

Anti-cancer drug made from soil bacteria

Scientists from the Helmholtz Centre for Infection Research (HZI) have discovered a class of natural substances that are produced by soil bacteria and prevent somatic cells from dividing.

19 Nov 2007

Pfizer to acquire Coley Pharmaceutical Group

Pfizer has announced that it has entered into an agreement to acquire Coley Pharmaceutical Group, a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.

19 Nov 2007

Age Intervention Eyelash products seized by U.S. Marshals

At the request of the U.S. Food and Drug Administration, U.S. Marshals seized today 12,682 applicator tubes of Age Intervention Eyelash, a product that may, in some users, lead to decreased vision.

19 Nov 2007

Eyelash growth product can damage vision

American consumers are being warned by the Food and Drug Administration (FDA) about the dangers of a product which promises to increase eyelash growth.

19 Nov 2007

New proposed monographs for dietary supplements

The U.S. Pharmacopeia (USP) is pleased to announce 11 new proposed monographs for dietary supplements for public notice and comment.

16 Nov 2007

FDA to improve advisory committee processes

The Food and Drug Administration is announcing several steps to strengthen its advisory committee processes in ways consistent with recommendations of the Institute of Medicine.

16 Nov 2007

Rising drug expenditures for ADHD

The NHS is likely to face a 10-fold increase in the cost of drugs prescribed to children and adolescents with attention-deficit/hyperactivity disorder (ADHD) in the decade to 2012.

16 Nov 2007

Drug to treat children with bipolar disorder gets priority review

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

15 Nov 2007

Top selling diabetes drug to carry back box warning

The government watchdog body in the U.S., The Food and Drug Administration (FDA), has placed a "black box" warning on the popular drug Avandia.

15 Nov 2007

GlaxoSmithKline implements changes to the US product label for Avandia

GlaxoSmithKline announced today that it is implementing changes to the US product label for Avandia(R) (rosiglitazone maleate), based on an extensive and thorough review by the FDA of myocardial ischemia data on Avandia, the most widely studied oral anti-diabetic medicine available.

15 Nov 2007

Petition aims to stem the flood of dangerous drugs reaching Americans

In a petition filed with the U.S. Food and Drug Administration, an international coalition of scientists and doctors seeks to compel the agency to stem the flood of dangerous drugs reaching American consumers by mandating the use of scientifically superior non-animal testing methods when those alternatives exist.

15 Nov 2007

FDA adds warning for heart attacks to type 2 diabetes drug Avandia

The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone), a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.

14 Nov 2007

Sanofi Pasteur and Acambis to bring West Nile vaccine to market

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive global collaboration agreement with Acambis plc, for the development and marketing of a West Nile vaccine to help fight against this serious, life-altering and potentially fatal disease.

14 Nov 2007

Pfizer and Nektar resolve outstanding Exubera contractual issues

Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.

14 Nov 2007